Wyeth 1Q

1Q Revenues: $5.4 billion (-6%)

1Q Earnings: $1.2 billion (flat)

Comments: Revenues would have risen 2%, were it not for the impact of a strengthening dollar. Enbrel sales (outside the U.S. and Canada) were $627 million (+3%). Prevnar sales were $755 million (+7%). Protonix sales were $215 million (+35%). Effexor sales were $819 million (-20%) and Zosyn sales $310 million (-9%), due to increased generic competition. Premarin sales were $246 million (-11)%.